Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The most effective method to Pick A Trade-in vehicle Stage - 2A definitive Burger Confrontation: Which One Rules?
- 3India's top court hears challenges to ruling on women's entry into temple
- 43 Italian City Cars That Outsmarted Regulations and Rivals
- 5Flu surges across U.S. as doctor visits reach highest level since 1997
- Asia's migrant workers debate if Gulf jobs are worth deadly risk of Iran war
- Russian military plane crashes in annexed Crimea, killing 29 people on board
- Striking American and European television Projects: A Survey
- A mom stopped giving her kids snacks — and sparked a debate about eating habits
- 5 Arising Professions in Environmentally friendly power
- New heart disease calculator predicts 30-year risk for young adults
- South Carolina measles outbreak grows by nearly 100, spreads to North Carolina and Ohio
- Southern Californians, your health insurance costs could rise in 2026
- A Colombian city swaps iconic horse buggies for electric carriages amid animal welfare concerns
